IsoRay Announces Study Accepted for Publication in The International Journal of Radiation Oncology, Biology, Physics entitled “Long-term Quality of Life in Prostate Cancer Patients Treated with Cesium-131”

At Median 5.5 Years Post-Treatment, Return to Baseline is Sustained RICHLAND, Wash., May 3, 2017 /PRNewswire/ -- IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of...

read more
ABS 2017 Insights and Takeaways

ABS 2017 Insights and Takeaways

A thorough discussion on value, detailed brachytherapy delivery techniques and ways clinicians can reach new patients: Isoray’s ABS 2017 insights and takeaways including Dr. Steven Frank, Dr. Alex Hsi and Harvard Business School Professor Emeritus Dr. Robert Kaplan.

read more

Isoray Patients Tell Their Stories

Herbert L   During Herbert’s initial diagnosis for localized prostate cancer, his physician advised that he see a urologist. After having tests run at the Chicago Prostate Cancer Center with Dr. Brian Moran, Herbert learned about his options for treatment, one of...

read more